Recent Medical News

Medical News
Walking and running comparably reduce CHD risk factors
Increasing exercise dose is beneficial while type of exercise does not affect risk reduction. (with teaching slides)
 
Walking versus running for hypertension, cholesterol, and diabetes mellitus risk reduction.

Literature - Williams PT, Thompson PD. - Arterioscler Thromb Vasc Biol. 2013 May;33(5):1085-91. doi: 10.1161/...
23/04/2013
Medical News
Elevated phosphate levels contribute to CV disease
Minimising dietary phosphate intake can limit cardiovascular tissue damage in CKD patients or even a broader population.
 
Phosphate: a novel cardiovascular risk factor.

Literature - Ketteler M, Wolf M, Hahn K, Ritz E. - Eur Heart J. 2013 Apr;34(15):1099-101. doi: 10.1093/eurheartj/ehs247.


Ketteler M, Wolf M, Hahn K, Ritz E...
23/04/2013
Medical News
CV risk factors in Latin America are comparable to the US
Less obesity than in the US, but similar rates of hypertension, diabetes and smoking
 
Major cardiovascular risk factors in Latin America: a comparison with the United States. The Latin American Consortium of Studies in Obesity (LASO).

Literature - Miranda JJ, Herrera VM, Chirinos JA, et...
20/04/2013
Medical News
Common CIMT does not improve risk assessment in patients with diabetes
USE-IMT meta-analysis shows that addition of common CIMT measurement to Framingham risk score has no added value for CV risk prediction
 
Common carotid intima-media thickness does not add to Framingham risk score in individuals with diabetes mellitus: the USE-IMT initiative.

Literature - den Ruijter HM, Peters SA, Groenewegen KA, et al....
19/04/2013
Medical News
Canadian guidelines: statins advised at 40 for diabetics
All patients with diabetes should start statin treatment at 40, and antihypertensive therapy from the age of 55, even in the absence of other risk factors
 
Canadian guidelines: statins advised at 40 for diabetics

News - Apr. 18, 2013
New guidelines from the Canadian Diabetes Association (CDA) state that all patients with diabetes should start taking statin...
18/04/2013
Medical News
Ventricular function, HF and risk of stroke/systemic embolism in AF
A retrospective analysis of the ARISTOTLE trial showed that  patients with LVSD had a higher risk of SSE or death compared with patients with HF but preserved LV systolic function; apixaban reduced the risk of both outcomes more than warfarin in all patient groups.
 
Left Ventricular Systolic Dysfunction, Heart Failure and the Risk of Stroke and Systemic Embolism in Patients with Atrial Fibrillation: Insights from the ARISTOTLE Trial.

Literature - McMurray JJ, Ezek...
16/04/2013
Medical News
Efficacy and safety of CETP inhibitors
Overview of currently available clinical data on this class of agents and their clinical benefit.
 
Systematic Review of CETP Inhibitors for Increasing High-Density Lipoprotein Cholesterol: Where Do These Agents Stand in the Approval Process?

Literature - Bishop BM. - Am J Ther. 2013 Apr 5. [Epub ahe...
14/04/2013
Medical News
Exploring the benefit of lower-than-recommended LDL-C levels
Review of available data on the effect and safety of very low LDL-C concentrations
 
Safety and effect of very low levels of low-density lipoprotein cholesterol on cardiovascular events.

Literature - Larosa JC, Pedersen TR, Somaratne R, Wasserman SM - Am J Cardiol. 2013 Apr 15;111(8):1...
12/04/2013
Medical News
Analysis of associations between CVD risk factors and socioeconomic factors over time
Cross-country analysis of metabolic risk factors gives insight into region-specific health challenges associated with affluence and life style
 
The global cardiovascular risk transition: associations of four metabolic risk factors with national income, urbanization, and Western diet in 1980 and 2008.

Literature - Danaei G, Singh GM, Paciorek C...
12/04/2013
Medical News
PCSK9 levels altered by simvastin, but not ezetimibe treatment
Changes in PCSK9 levels are affected by decreasing LDL-C levels and PCSK9 baseline levels.
 
Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels.

Literature - Berthold HK, Seidah NG, Benjannet S, and Gouni-Berthold I. - PLoS One. 2013;8(3)...
11/04/2013
Medical News
Addition of ezetimibe to statin therapy effectively lowers LDL-C
More patients attain LDL-C goals after addition of ezetimibe to statin treatment in COURAGE trial.
 
 

Literature - Maron DJ, Hartigan PM, Neff DR, et al and COURAGE Trial Investigators. - Am J Cardiol. 2013 Mar 25. doi: 10.1016/j.amjcard.2013.02.005
Impact of Adding Ezetimibe to Statin to Achieve Low-...
05/04/2013
Medical News
Statins often tolerated after supposed statin-related event
Tolerance after rechallenging with statins after a statin-related event indicates that side-effects may not be truly drug-related.
 
Discontinuation of Statins in Routine Care Settings: A Cohort Study

Literature - Zhang H, Plutzky J, Skentzos S et al. - Ann Intern Med. 2013;158:526-534.
 

Zhang H, Plutzky J, Skentzos S et al.

Ann Inter...
04/04/2013
Medical News
No evidence for higher bleeding incidence in real world dabigatran-treated patients
Similar efficacy but lower mortality,  intracranial bleeding, myocardial infarction and pulmonary embolism after dabigatran treatment vs. warfarin
 
Efficacy and safety of dabigatran etexilate and warfarin in ‘real world’ patients with atrial fibrillation: A prospective nationwide cohort study.

Literature - Larsen TB, Rasmussen LH, Skjoth F et al.,...
03/04/2013
Medical News
The interplay of insulin metabolism and atherosclerosis
Discussion of the anti- and proatherogenic effects of insulin in type 2 diabetes
 
Insulin and atherosclerosis: How are they related?

Literature - Monnier L, Hanefeld M, Schnell O et al. - Diabetes Metab. 2013 Mar 15.. doi: 10.1016/j.diabet.2013.02.001


Monnier L, Hanefeld M, Schnell O...
02/04/2013
Medical News
New therapeutic strategies to treat dyslipidaemie
Mechanistic insights have yielded new therapeutic strategies to reduce LDL-C and Lp(a). An overview is given of therapeutic approaches that are currently under evaluation.
 
Interfering with lipoprotein synthesis

Literature - Norata GD, Ballantyne CM, Catapano AL - Eur Heart J. 2013 Mar 18


New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs.
No...
30/03/2013
Medical News
Azilsartan gives better and persistent reduction in blood pressure than ramipril
Better reduction in SBP and DBP obtained with 40 or 80 mg AZL-M than with 10 mg RAM, without increasing adverse effects.
 
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.

Literature - Bönner G, Bakris GL, Sica D et al - J...
29/03/2013

• Previous
• 1
• 2
• …
• 157
• 158
• 159
• 160
• 161
• …
• 167
• 168
• Next